Preventing C. diff infection with vancomycin
Part of Infections clinical trials.
This trial tests whether taking vancomycin by mouth can prevent another C. diff infection when you need to take other antibiotics. It’s for patients who recently had C. diff and are about to start a new antibiotic course.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have had a C. diff infection in the last 120 days that was treated successfully with vancomycin or fidaxomicin for at least 10 days.
- You are now starting a new course of antibiotics (taken by mouth or through a vein) that will last at least a few days.
- You have not had a colostomy, ileostomy, or colon removal.
- You can take medications by mouth.
- You have not received a fecal transplant or other microbiome therapy for this C. diff episode.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares three treatments for a severe diarrhea infection called C. diff: a fecal transplant (putting healthy donor stool into your gut), a newer antibiotic called fidaxomicin, and an older antibiotic called vancomycin. The goal is to see which works best and prevents the infection from coming back.
This study tests two antibiotics—fidaxomicin and vancomycin—to see which is better at clearing C. difficile bacteria from the gut in people with inflammatory bowel disease. If you are having a colonoscopy, you may be able to participate.
This study tests a new live bacteria product (EXL01) given with vancomycin to prevent C. diff from coming back. It is for people who have already had C. diff two or more times and are at high risk of another infection.
This study tests a new antibody (AZD5148) to prevent C. diff infection from coming back. If you have a current C. diff infection and are being treated with antibiotics, you may be able to join.
This study tests whether taking a capsule form of fecal microbiota transplant (FMT) can help adults with their first C. difficile infection—or a first relapse—get better and reduce repeat episodes. Participants also take specific antibiotics for C. difficile as part of the study process.
This trial tests a new medicine called VE303, a live bacterial therapy, to prevent C. diff infections from coming back. It is for people who have had C. diff at least once in the last 6 months, or who are at high risk for a repeat infection due to age or other health problems.
Hear when a new Clostridioides Difficile Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.